A Study Of Chemo Sensitivity Cell Viability Assay

Overview

About this study

The aim is to develop and implement a laboratory test designed to assess the viability of isolated cancer cells when exposed to various chemotherapy drug combinations ex vivo. This test will evaluate drug-induced cytotoxicity to hematological malignant cells. Biospecimens will be used to evaluate and validate that the laboratory test performs as expected (performance characteristics) with the goal of implementing a laboratory test.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Subjects diagnosed with the following diagnoses that are treatment naïve, relapsed, or in treatment (not historical diagnoses):

    • malignant lymphoma

    • acute and chronic leukemias

    • plasma cell disorders

 Exclusion Criteria:

  • Subjects not diagnosed with a hematological malignancy of interest, subjects declining consent, or “cured” of hematological malignancy.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 9/25/2025. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Rondell Graham

Open for enrollment

Contact information:

Janessa Gore

(507) 266-0853

gore.janessa@mayo.edu

More information

Publications

Publications are currently not available